Cell News and Research

RSS

Researchers use BEZ235 drug to eliminate NSCL cancer

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

30 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

Physician-researchers at the University of Southern California (USC) received a nearly $16 million grant from the California Institute of Regenerative Medicine (CIRM) to fund the development of a stem cell-based treatment for age-related macular degeneration, the leading cause of vision loss and blindness among the elderly.

29 Oct 2009

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

A team of Cedars-Sinai Heart Institute stem cell researchers led by Eduardo Marb-n, M.D., Ph.D. has been awarded a four-year, $5.5 million grant from the California Institute of Regenerative Medicine (CIRM) to fund research leading to clinical trials of new treatments for heart attack patients.

29 Oct 2009

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Xenomics sues Sequenom

Xenomics, Inc. a developer of trans-renal molecular diagnostic technologies, announced today that it has filed a complaint against Sequenom, Inc. in the Supreme Court of the State of New York alleging that Sequenom fraudulently misrepresented to Xenomics the status of its testing for Down Syndrome and based upon such conduct, Xenomics was induced to enter into a license agreement with Sequenom thereby giving up various valuable patent rights.

29 Oct 2009

Ventas reports substantial growth in third quarter 2009

Ventas, Inc. (“Ventas” or the “Company”) said today that third quarter 2009 normalized Funds From Operations (“FFO”) increased 7.4 percent to $103.4 million, from $96.2 million for the comparable 2008 period. Normalized FFO per diluted common share was $0.66 in the third quarter of 2009, compared to $0.68 in the comparable 2008 period. Weighted average diluted shares outstanding in the third quarter of 2009 were 156.5 million, compared to 141.1 million in the comparable 2008 period.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Interleukin Genetics and Amway Global sign partnership agreement

Interleukin Genetics, Inc. announced today it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM) brand of genetic tests, including the new Weight Management Genetic Test.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Curis

Curis, Inc., a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the third quarter ended September 30, 2009.

29 Oct 2009

Seminar on multiple myeloma

MediCom Worldwide, Inc., an accredited provider of continuing medical education for physicians, pharmacists, and nurses, announces a Friday Satellite Symposium on Multiple Myeloma Preceding the 51st ASH Annual Meeting entitled Unifying Practice Patterns Among Academic and Community Clinicians: Focus on Myeloma.

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

Fresenius Kabi to license its proprietary HESylation Technology to Octapharma

Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

29 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

National study to prevent strokes in children and adolescents with sickle cell anemia

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

29 Oct 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Cell News and Research

Researchers use BEZ235 drug to eliminate NSCL cancer

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

CIRM awards Cedars-Sinai Heart Institute $5.5 million grant for development of cardiac stem cell therapies

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Xenomics sues Sequenom

Ventas reports substantial growth in third quarter 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Interleukin Genetics and Amway Global sign partnership agreement

Third-quarter 2009 financial results of Antigenics announced

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

Third-quarter fiscal 2009 results announced by Curis

Seminar on multiple myeloma

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

Fresenius Kabi to license its proprietary HESylation Technology to Octapharma

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

National study to prevent strokes in children and adolescents with sickle cell anemia

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News